title: Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study.
authors.forename: Ana
authors.initials: A
authors.lastname: Canestri
authors.forename: Mamadou
authors.initials: M
authors.lastname: Cisse
authors.forename: Anne-Geneviève
authors.initials: AG
authors.lastname: Marcelin
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Traore
authors.forename: Lambert
authors.initials: L
authors.lastname: Assoumou
authors.forename: Ousmane
authors.initials: O
authors.lastname: Traore
authors.forename: Victoria
authors.initials: V
authors.lastname: Koita
authors.forename: Fodie
authors.initials: F
authors.lastname: Diallo
authors.forename: Awa Thiero
authors.initials: AT
authors.lastname: Sangare
authors.forename: Mayrama Koita
authors.initials: MK
authors.lastname: Sidibé
authors.forename: Vincent
authors.initials: V
authors.lastname: Calvez
authors.forename: Aliou
authors.initials: A
authors.lastname: Sylla
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Roland
authors.initials: R
authors.lastname: Tubiana
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008302:Mali; D008875:Middle Aged; D010865:Pilot Projects; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D017320:HIV Protease Inhibitors; D019469:Indinavir; D019438:Ritonavir